First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Opinion
Video

Experts provide the first report of results from the Phase 3 PhALLCON trial comparing initial therapy with ponatinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content
A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.

Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL

Roman Fabbricatore
April 21st 2025
Article

A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

HSCT Recipients Show Sustained Health Challenges Following Transplant

Roman Fabbricatore
March 25th 2025
Article

Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.

Highlighting Developments and Informing Treatment Planning in CLL Care

Roman Fabbricatore
March 13th 2025
Article

Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.

CHMP Recommends Pirtobrutinib for EU Approval in Pretreated R/R CLL

CHMP Recommends Pirtobrutinib for EU Approval in Pretreated R/R CLL

Tim Cortese
March 3rd 2025
Article

Pirtobrutinib demonstrated PFS benefit compared with standard of care in patients with relapsed or refractory CLL in the BRUIN CLL-321 trial.